Welcome to the
Hepatitis B Foundation
Hepatera Completes Enrollment of Phase IIa Clinical Trial of Myrcludex B, for HBV
March 10 – A group of 48 patients infected with the hepatitis B virus have been enrolled in the phase IIa clinical trial of Myrcludex B by Russian biotech company Hepatera Ltd., with the aim to study safety, tolerability and efficacy. Read more.
Metabolic Profiling of Liver Cells Suggests New Treatments for Cirrhosis Patients
March 10 – In a new study that could help doctors extend the lives of patients awaiting liver transplants, a Rice University–led team of researchers examined the metabolic breakdown that takes place in liver cells during late–stage cirrhosis and found clues that suggest new treatments to delay liver failure. Read more.
Biostar Pharmaceuticals, Inc. Partners with Shaanxi University of Chinese Medicine to Co-develop Liver Cancer Drug
March 10 – Biostar Pharmaceuticals, Inc., a China–based manufacturer and marketer of pharmaceutical and health supplement products, announced that it has signed a letter of intent with the Research Institute of Pharmaceuticals at Shaanxi University of Chinese Medicine to develop a new liver cancer drug based on Oleanolic Acid injection. Read more.
Hepatitis B Foundation and Hep B United Applaud USPSTF for Draft HBV Screening Recommendations
Feb. 10 - The United States Preventive Services Task Force (USPSTF) issued a draft “B” grade for HBV screening of populations most vulnerable to HBV infection, which includes foreign-born individuals from countries with a 2% or higher HBV prevalence rate. A "B" grade recommendation ensures that healthcare providers will increase HBV screening in high-risk populations and that insurance carriers will reimburse for the testing! Read more.
Dr. Robert Gish Becomes Medical Director for Hepatitis B Foundation
Feb 10 - An internationally renowned medical researcher in the field of viral hepatitis, Dr. Gish has made invaluable contributions to the understanding and treatment of hepatitis B, which is the world’s leading cause of liver cancer. A longtime supporter of the foundation’s mission and a member of the Scientific Advisory Board, Dr. Gish’s new role will further strengthen its research and advocacy efforts worldwide. Read more.
Page last modified March 10, 2014